Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SST-5058
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk.
Product Name : SST-5058
Product Type : Antibody
Upfront Cash : Inapplicable
July 21, 2020
Lead Product(s) : SST-5058
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Novo Nordisk
Deal Size : Inapplicable
Deal Type : Inapplicable